Pharmacogenomics J. 2009 May 19. Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening? Laika B, Leucht S, Heres S, Steimer W. Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, Technische Universität München, München, Germany. The cytochrome P450 2D6 (CYP2D6) isoenzyme metabolizes about 25% of [...]
Filed under: Personalized Medicine | Tagged: 2Dy, CYP2D6, Cytochrome, Personalized Medicine, Pharmacogenetics | Leave a Comment »
